Meeting to be held in New York on October 8-9 hosted by Piper Sandler.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TENX:
- Optimistic Buy Rating for Tenax Therapeutics Driven by Strong Patent Portfolio and Market Potential of Levosimendan
- Tenax announces EPO intention to grant patent for levosimendan in PH-HFpEF
- Tenax Therapeutics Expands Licensing Agreement with Orion
- Promising Potential of Tenax Therapeutics’ TNX-103 Drives Buy Rating Amid Positive Phase 2 Results and Anticipated Phase 3 Trial
- Tenax Therapeutics initiated with an Overweight at Piper Sandler